Oct 30, 2026 earnings call — Pipeline momentum and new launches drive growth
Total revenue grew 7% and core EPS increased 14% in the first 9 months of 2026.
Revenue $16.2B (est $16.0B) · EPS $2.79 (est $2.60)
Key quotes
"Together, these positive readouts represent more than $10 billion in nonrisk-adjusted peak year sales potential, maintaining the scale of opportunity we outlined at the start of the year."
"With commercial momentum continuing and a deep late-stage pipeline advancing, we are increasingly confident in our ability to deliver our 2030 ambition as well as sustainable long-term growth through the next decade."
"Today, we're also announcing the Reshaping for Sustainable Growth program, a 3-year initiative to redeploy resources and strengthen capabilities across AstraZeneca's existing businesses and therapy areas."